If, like this Kat, you love all things pharma, biotech and patents, then the Pharma & Biotech Patent Litigation in Europe conference is for you. The IPKat is also happy to report that there is a special 10% discount in the registration fee, with discount code: D10-999-IPKAT26.
 |
| Catching up on pharma IP case law in Amsterdam |
The conference will be held over 2 days in central Amsterdam. Highlights on the agenda this year include:
- The Rise of Cross-Border Patent Enforcement: Redesigning European Patent Litigation Strategy Post-BSH v Electrolux.
- Running and Defending Preliminary Injunctions at the UPC and Beyond: Reconciling Diverging Standards and Making Strategic Choices for Life Sciences.
- Antibody Patent Prosecution in the EU and the US.
- The Doctrine of Equivalence: Balancing the UPC's First Approach Against Contrasting UK and German Decisions.
- Claim Interpretation, Description Conflicts, and the Next Chapter in Life Sciences after G 1/24 and G 1/25.
- Regulatory Exclusivities and IP After the EU Pharma Package: Key Takeaways for Industry and Litigators.
- Skinny Labels as a Safe Harbour? Second Medical Use Patents and Evolving Infringement Liability in Europe and the US.
If all this weren't enough, Amsterdam also happens to be host to the only floating cat shelter in the world, De Poezenboot, and an art museum devoted entirely to feline art. Not to be missed!
More details and registration on the conference website.
Pharma & Biotech Patent Litigation in Europe conference returns with IPKat readers’ discount
Reviewed by Dr Rose Hughes
on
Friday, April 24, 2026
Rating:
Reviewed by Dr Rose Hughes
on
Friday, April 24, 2026
Rating:
Follow the IPKat on LinkedIn 
No comments:
All comments must be moderated by a member of the IPKat team before they appear on the blog. Comments will not be allowed if the contravene the IPKat policy that readers' comments should not be obscene or defamatory; they should not consist of ad hominem attacks on members of the blog team or other comment-posters and they should make a constructive contribution to the discussion of the post on which they purport to comment.
It is also the IPKat policy that comments should not be made completely anonymously, and users should use a consistent name or pseudonym (which should not itself be defamatory or obscene, or that of another real person), either in the "identity" field, or at the beginning of the comment. Current practice is to, however, allow a limited number of comments that contravene this policy, provided that the comment has a high degree of relevance and the comment chain does not become too difficult to follow.
Learn more here: http://ipkitten.blogspot.com/p/want-to-complain.html